Clinical trial
Dose Escalation Study for Primary Hepatocellular Carcinoma
NCT00243841 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00243841 |
|---|---|
| Title | Dose Escalation Study for Primary Hepatocellular Carcinoma |
| Official title | Multi-institution Phase I/II Dose Escalation Study of Hypofractionated Stereotactic Body Radiation Therapy for Primary Hepatocellular Carcinoma |
| Acronym | SBF-HCC |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | University of Colorado, Denver |
| Status | Completed |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Radiation |
| Interventions | Stereotactic Body Radiation |
| Enrollment | 77 |
| Start date | May 1, 2004 |
| Primary completion | Dec 31, 2016 |
| Completion | Dec 31, 2016 |
| First posted | Oct 25, 2005 |
| Last update posted | Dec 13, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: